Oncological outcomes of surgical treatment for T3 supraglottic laryngeal squamous cell carcinoma patients

Abstract

Background: T3 supraglottic laryngeal carcinoma (LC) is a common advanced laryngeal cancer.

Objective: This study was conducted to assess the clinical results of pathological T3 (pT3) supraglottic LC patients who were amenable to laryngectomy treated with primary surgery and postoperative therapy.

Methods: Retrospective review of 202 pT3 cases of supraglottic laryngeal squamous cell carcinoma.

Results: The five-year cancer specific survival (CSS) rate was 63.7% and the overall survival rate (OS) was 62.8%. For T3 supraglottic patients who underwent total laryngectomy, the five-year disease-free survival (DFS) was 51.8%, and the CSS was 62.5%. For patients who underwent partial laryngectomy, the five-year DFS was 72.2%, and the CSS was 79.0%. High lymph node and stage status are predictors of mortality for these patients. No difference was found in the DFS and CSS rates between patients with negative margins and those with positive margins following postoperative radiotherapy and chemotherapy.

Conclusion: Surgical treatment of T3 supraglottic LC patients achieved satisfactory results. Postoperative radiotherapy and chemotherapy are an effective method of treatment for T3 supraglottic LC patients, especially for those with a positive margin.

Chinese abstract

背景：T3声门上喉癌是一种常见的晚期喉癌。

目的：评价经一期手术和术后治疗的病理性T3（pT3）声门上型LC患者接受喉切除术的临床效果。

方法：回顾性分析202例pT3声门上喉鳞状细胞癌的临床资料。

结果：5年肿瘤特异性生存率（CSS）为63.7%, 总生存率（OS）为62.8%。对于接受全喉切除术的T3声门上喉癌患者, 5年无病生存率（DFS）为51.8%, CSS为62.5%。对于接受部分喉切除术的患者, 5年的DFS为72.2%, CSS为79.0%。高淋巴结和发展期是这些患者死亡率的预测因素。术后放疗和化疗后, 负边缘患者和正边缘患者的DFS和CSS率无差异。

结论：T3声门上型LC患者的手术治疗取得了满意的效果。术后放疗和化疗是治疗T3声门上型LC患者的有效方法, 尤其是对于边缘阳性的患者。

Keywords:

• Laryngectomy
• supraglottic laryngeal squamous cell carcinoma
• survival
• T3

Disclosure statement

No potential conflict of interest was reported by the authors.